Larysa Mishchenko

Scopus Publications

Clinical-functional features and changes in psycho-emotional state in patients with arterial hypertension – participants of combat operations in Ukraine
O. G. Kupchynska, L. A. Mishchenko, V. G. Lyzogub, L. V. Bezrodna, O. O. Matova, G. M. Boghenko
Ukrainian Journal of Cardiology, 2025
The aim – to investigate the clinical features, the nature of the daily rhythm of blood pressure, target organ damage and the psycho-emotional state of patients with hypertension who were direct participants in the military conflict in Ukraine.Materials and methods. The analysis of the features of the course of hypertension was carried out in 58 men who were direct participants in the hostilities of the military conflict in Ukraine. Patients were divided into groups depending on the time of onset of hypertension, the presence or absence of signs of anxiety and depression according to the HADS hospital scale, the presence or absence of previous acubarotrauma. Objective condition, adherence to treatment, presence and nature of cognitive function disorders, psychoemotional status, results of daily blood pressure monitoring, morphofunctional condition of the left ventricle, functional condition of kidneys, and lipid metabolism were analyzed. The control group (CG) consisted of 36 male patients with АН, comparable in age, body mass index, initial values of blood pressure (DP), and the presence of concomitant pathology, who were examined and treated in the department of arterial hypertension and comorbid pathology before the start of hostilities in Ukraine.Results and discussion. In 51.7 % of the examined, hypertension was already detected during the participation in hostilities in Ukraine. Most of the examined (53.4 %) had obesity of the first or second degree, another 31.0 % were overweight. Before entering the department, 81.0 % of patients were taking antihypertensive drugs, but the vast majority of them (72.3 %) had low adherence to treatment. Cognitive disorders according to the MMSE scale were found in 31 % of patients, psychosomatic disorders according to the HADS anxiety and depression scale – in 58.6 %. For patients with a long course of hypertension and with psychosomatic changes, a violation of the daily rhythm of blood pressure (ВР) according to the «non-dipper» type was characteristic, and for patients with recent hypertension and those who underwent acubarotrauma – an increase in the variability of ВР. Signs of remodeling of the left ventricle (91.4 %) were found in almost all of the examined subjects, while the vast majority (87.9 %) showed concentric changes in it, as well as disturbances in the lipid spectrum of the blood (93.1 %). The most significant changes in the lipid profile were characteristic of patients with acubarotrauma. The identified changes are factors that have a negative impact on the course of hypertension and the prognosis of patients.Conclusions. Direct participation in combat operations is often accompanied by the appearance of signs of anxiety and depression, increased blood pressure variability and insufficient reduction during sleep, contributes to the development of concentric changes in the left ventricle of the heart; such patients, especially after acubarotrauma, have significant disturbances in the lipid spectrum of the blood. Most of such patients have low adherence to treatment. All this must be taken into account when choosing treatment tactics for such patients.
Characteristics of cardiovascular risk factors in hypertensive patients taking a dual combination of antihypertensive drugs: results of the FACTOR-duo study
L. A. Mishchenko, O. O. Matova
Ukrainian Journal of Cardiology, 2024
The aim – to study the characteristics of cardiovascular risk factors, the structure and effectiveness of treatment in hypertensive patients (pts) on the background of a dual combination of antihypertensive drugs, to evaluate the efficacy and tolerability of calcium channel blockers (CCB) (amlodipine and lercanidipine) when added to the combination of renin-angiotensin-aldosterone system (RAAS) inhibitor with a diuretic.Materials and methods. A multicenter study with 1616 hypertensive pts who received dual combination antihypertensive therapy. Cardiovascular risk factors were studied (smoking status, alcohol consumption, physical activity, family history of cardiovascular disease), concomitant cardiovascular diseases, carbohydrate metabolism disorders, and body mass index were determined, and current antihypertensive therapy and its effectiveness were evaluated based on office blood pressure (BP) measurements. Amlodipine 5-10 mg/day or lercanidipine 10–20 mg/day was added to the combination of RAAS blocker with a diuretic in the case of office BP ≥ 140/90 mm Hg. 1198 hypertensive pts received triple combined therapy. The effectiveness and tolerability of the treatment were evaluated after 4 weeks according to data from office BP measurements and home BP monitoring (HBPM). Lercanidipine was taken by 76 % of pts and amlodipine was taken by 24 % of pts.Results and discussion. Hypertensive pts were characterized by a significant prevalence of obesity (38.6 %), smoking (27.9 %), and insufficient physical activity (31.2 %). A significantly higher percentage of smoking and alcohol consumption was registered among men, while a lower level of physical activity was registered among women. Concomitant type 2 diabetes was present in almost a quarter of pts, stroke/TIA in 8.7 %, and myocardial infarction/revascularization in 8.3 %. At the same time, 53.2 % of the pts received statin therapy, and 64.7 % received antiplatelet drugs.Conclusions. The addition of CCB contributed to office BP target achievement in 69.1 % of pts, and optimal BP according to HBPM data in 54.3 % of pts. Lercanidipine and amlodipine have demonstrated comparable antihypertensive efficacy. Lercanidipine demonstrated a better tolerability profile compared to amlodipine: the incidence of side effects was significantly lower, respectively, 3.6 vs. 12.3 %; edema of the lower legs occurred in 6.5 times more often under amlodipine treatment than lercanidipine.
Predictors of cardiovascular and renal complications in patients with resistant arterial hypertension during long-term follow-up
O. O. Matova, L. А. Mishchenko, T. V. Talayeva, O. B. Kuchmenko
Ukrainian Journal of Cardiology, 2024
The aim – to evaluate the incidence of cardiovascular and renal complications and its predictors in resistant hypertensive (RH) patients during the long-term follow-up.Materials and methods. The frequency of cardiovascular and renal events was studied in 240 true resistant hypertensive patients. The duration of observation was 5.1±0.1 years. The comparison group consisted of 228 patients with controlled arterial hypertension (CAH) on a triple combination antihypertensive therapy. Cardiovascular endpoints included stroke/transient ischemic attack, myocardial infarction, cardiovascular death, myocardial revascularization, development of atrial fibrillation, hospitalization due to heart failure, and lower limb arterial disease. Kidney outcomes included dialysis or GFR decline by 40 % or greater. All the endpoints formed a composite primary endpoint. New cases of type 2 diabetes mellitus were also estimated.Results and discussion. The patients with resistant hypertension on multi-component antihypertensive therapy and significant reduction in arterial blood pressure (BP) levels (achievement of controlled office BP in 49.6 % of patients, office and ambulatory BP in 34.2 % of patients), maintained a higher risk of cardiovascular and renal events compared to patients with controlled arterial hypertension. It was found that the frequency of occurrence of the composite primary endpoint in resistant hypertensive patients was four times higher than in the group of patients with controlled hypertension – 30.0 % (72/240) versus 7.0 % (16/228) (p=0.001). The frequency of new cases of type 2 diabetes mellitus in patients with RH exceeded compared to CAH patients by 3.7 times (p=0.03).Conclusions. Independent predictors of the risk of cardiovascular and renal complications in patients with RH were the initial indicators of circulating endothelial progenitor cells if their concentration in the blood was ≤ 1818 cells/ml (HR 0.41; 95 % CI (0.21–0.79); p=0.007), the content of citrulline in the blood is more than 68 μmol/l (HR 1.13; 95 % CI (1.07–1.20); p<0.001); value of initial average daily systolic BP > 163 mm Hg (HR 1.10; 95 % CI (1.03–1.18); p=0.008).
Lipid-lowering potential of a complex dietary supplement for cholesterol control and vascular protection
Larysa Mishchenko, Olena Matova
Family Medicine European Practices, 2024
The objective: to analyze the lipid-lowering effect of a complex dietary supplement containing red fermented rice extract, bergamot extract and 5-methyltetrahydrofolate in patients with low, moderate and high cardiovascular risk (CVR) or patients who refused to use statins.Materials and methods. The open-label post-marketing study included 60 patients aged 48.1±0.7 years, 54 (90%) persons of whom were women. According to the results of the assessment of total CVR, most patients were in the low/moderate and high risk categories – 47 (78.3%) and 13 (21.7%) individuals, respectively, the last patients refused to use statins. Overweight and obesity were detected in 50% of the study participants – 24 (40%) and 6 (10%) people with degree I obesity, respectively. Arterial hypertension with a grade 1 increase in blood pressure was present in 45% of the study participants (27 persons, all women).Patients were prescribed a complex dietary supplement containing red fermented rice extract, bergamot extract, and 5-methyltetrahydrofolate in clearly defined doses for 3 months. At the screening stage and the final visit all patients underwent a general clinical and laboratory examination.Results. The use of a complex dietary supplement for cholesterol control and vascular protection for 3 months contributed to a decrease in total cholesterol (TC) by 8.1% (p=0.0001), low-density lipoprotein cholesterol (LDL-C) by 14.3% (p=0.0001), non-HDL-C by 12.5% (p=0.0001) and an increase in high-density lipoprotein cholesterol (HDL-C) by 7.1% (p=0.02).In patients with a baseline triglyceride (TG) level (>1.7 mmol/l), a significant reduction of 18.5% (p=0.04) was found, and in patients with signs of systemic inflammation the level of C-reactive protein (CRP) was >3 mg/ml. The use of a dietary supplement helped to reduce CRP by 33.3% (p=0.008).Positive dynamics of the albumin to creatinine ratio in patients with more severe albuminuria was determined. The results of the study indicate that the use of a dietary supplement containing red fermented rice extract, bergamot extract and 5-methyltetrahydrofolate does not affect carbohydrate metabolism and liver function tests.Conclusions. A dietary supplement containing a scientifically based combination of substances of natural origin for the normalization of lipid profile has a positive effect on lipid profile parameters, contributing to a decrease in LDL-C and TG levels in individuals with baseline hypertriglyceridemia and an increase in HDL-C content.The dietary supplement, which contains red fermented rice extract, bergamot extract and 5-methyltetrahydrofolate, improves endothelial function, as evidenced by a decrease in albuminuria and low-grade systemic inflammation in individuals with higher baseline vaules.
The improvement of endothelial function by inhibition of platelet activity using acetylsalicylic acid in patients with arterial hypertension
, Tatyana Talaieva, Larysa Mishchenko, Iryna Tretyak, Olena Matova, Natalia Vasilinchuk, Larysa Vavilova
Cell and Organ Transplantology, 2023
In accordance with modern ideas about the pathogenesis of thrombotic complications of cardiovascular diseases (myocardial infarction, stroke), it should be noted that platelets and platelet humoral factors play a key role in the development of thrombosis. Activated platelets are able to activate both endotheliocytes and pro-inflammatory cells - monocytes/macrophages, which take a direct part in the formation and progression of atherosclerotic plaque. The purpose of the study is to investigate the potential improvement of endothelial function through the inhibition of platelet activity using acetylsalicylic acid in patients with arterial hypertension and established atherosclerotic cardiovascular diseases. Materials and methods. We enrolled 41 patients with arterial hypertension and established atherosclerotic cardiovascular diseases in our study. The participants were divided into two groups. Group 1 comprised 20 patients who were already taking acetylsalicylic acid (ASA) before the study, while Group 2 consisted of 21 patients who had not received ASA before participating. During the 6-month study period, patients from both groups received ASA (75 mg once a day) as part of their basic therapy, which included antihypertensive and statin therapy. Platelet activity was assessed in all patients before the study and at the final stage by determining the expression of glycoproteins GPIIb-IIIa and P-selectin on their surface. Additionally, the content of endothelial progenitor cells (phenotype CD45-CD31+CD133+) and desquamated endothelial cells (phenotype CD45-CD31+CD133-) in the blood was analyzed using flow cytometry. ELISA was employed to measure the content of C-reactive protein, cytokines TNF-α and IL-10, as well as asymmetric dimethylarginine (ADMA) in the blood. Finally, all patients underwent a test with flow-dependent vasodilation of the brachial artery. Results. In patients who did not receive ASA before the study, there was a higher level of platelet activity in peripheral blood flow, along with signs of more pronounced endothelial dysfunction compared to those who received it. After 6 months of taking ASA alongside standard antihypertensive therapy, the activation level of circulating blood platelets decreased in both groups. Specifically, in patients of group 1, the expression level of CD41 (GPIIb) decreased by 31.8 % (p < 0.01), and CD61 (GPIIIa) decreased by 15.2 % (p < 0.01). In group 2 patients, the suppression of platelet activity was even more pronounced, with the expression level of CD41 (GPIIb) decreasing by 55.2 % (p < 0.001), and CD61 (GPIIIa) decreasing by 27.5 % (p < 0.05). Furthermore, in patients of group 1, the percentage of platelets carrying P-selectin on the surface decreased by 78.1 % (p < 0.01). In group 2, the number of such platelets also significantly decreased by 42.5 % (p < 0.05). The number of progenitor cells of endothelial cells in the circulating blood increased significantly in both groups, showing a 3-fold increase in patients of group 1 (p < 0.001) and a 2.3-fold increase in patients of group 2 ( p< 0.001). In patients of both groups, a significant 2-fold increase in the endothelium-dependent vasodilatation index was observed (p < 0.01). At the end of the study, there was a decrease in the blood level of CRP by 12.2 % and 18.8 %, and pro-inflammatory cytokine TNF-α decreased by 50% and 57 %, respectively, in patients of groups 1 and 2 (p < 0.001). Conclusion. The reduction in blood platelet activity triggered by ASA in patients with arterial hypertension and atherosclerotic cardiovascular diseases was associated with notable alterations in the intensity of systemic inflammation and the restoration of endothelial functions. These findings suggest a potential therapeutic role for ASA in modulating both platelet function and endothelial health in individuals with these conditions.
HEALTH CARE FOR WOMEN IN MENOPAUSE Clinical lecture for general practitioners – family doctors
O.M. Barna, O.О. Yefimenko, N.V. Kosei, L.A. Mishchenko, N.Y. Pedachenko, T.F. Tatarchuk
Reproductive Endocrinology, 2023
Clinical lecture is intended for general practitioners – family doctors who provide medical assistance to women with menopausal disorders and are based on the Unified clinical protocol of primary, secondary (specialized), tertiary (highly specialized) heath care “Menopausal disorders and other disorders in the perimenopause” approved by the order of the Ministry of Health of Ukraine dated June 17, 2022 No. 1039.Clinical lecture provides methods and algorithms for diagnosis and treatment of associated with menopause disorders, which will allow forming a comprehensive management strategy of women during menopause by a family doctor in Ukraine and will contribute to improving their health and quality of life.Today, there are no reliable signs that predict the severity and duration of menopausal disorders, so women should focus on a healthy lifestyle as a way to prevent severe menopausal disorders.To clarify the stages of reproductive aging, it is advisable to use the Stages of Reproductive Aging Workshop (STRAW+10). All women over 40 who come for a visit should be asked 6 questions to identify menopausal syndrome. The international Menopause Rating Scale is used to determine the severity of menopause symptoms. Women with symptoms of menopause should be referred to an obstetrician-gynecologist. Treatment of patients with menopausal disorders is carried out by a general practitioner –a family doctor and is carried out using non-medicinal methods and pharmacotherapy. The family doctor can prescribe non-hormonal drugs. Hormonal treatment of menopause symptoms is prescribed by an obstetrician-gynecologist. Treatment of accompanying pathology is prescribed by relevant specialists in accordance with current standards of medical care. Patients with perimenopausal and menopausal disorders need to be monitored by a general practitioner – a family doctor, who maintains the medical documentation and helps the patient comply with the recommendations of specialists.
May Measurement Month 2017-2019: an analysis of blood pressure screening results from Ukraine
Larysa A Mishchenko, Tetyana V Kolesnik, Tetyana A Khomazyuk, Yurii M Sirenko, Serhiy V Fedorov, Wei Wang, Thomas Beaney, Neil R Poulter, Liliya I Zelenenka, Olena O Matova, Olena Yevstigneeva
European Heart Journal Supplement, 2022
Hypertension is a key cardiovascular disease risk factor leading to premature mortality worldwide. The purpose of the May Measurement Month (MMM) campaign in Ukraine is to improve awareness of hypertension at the individual and population level. Adults (≥18 years) were screened at sites in Ukraine. Data from the MMM17 (19 sites), MMM18 (1 site), and MMM19 (5 sites) campaigns are included in the present analysis. Ideally, three blood pressure (BP) measurements were taken for each participant, and data on lifestyle factors and comorbidities were collected. Hypertension was defined as systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mm Hg (based on the mean of the second and third readings) or being on antihypertension medication. Multiple imputation was used to estimate participants’ mean BP where readings were missing. Linear regression models were used to evaluate associations between BP and participant characteristics. Of all 46 549 screenees, 33 307 (71.6%) had hypertension, and 82.6% of whom were on antihypertensive medication. Of all those on medication, 31.4% were controlled to BP &lt; 140/90 mmHg, and of all 33 307 participants with hypertension, 25.9% had controlled BP. Of all participants, 6.6% took statins and 11.2% took aspirin. The analysis of the MMM 2017, 2018, and 2019 campaigns has shown a high proportion of hypertension, insufficient level of awareness, and critically low level of effective BP control in Ukraine. Further MMM screening is needed to increase awareness of high BP and to help improve diagnosis, management, and treatment of hypertension.
CARDIOVASCULAR AND KIDNEY OUTCOMES IN TREATED RESISTANT HYPERTENSIVE PATIENTS
Olena Matova, Larysa Mishchenko, Tatyana Talaeva
Journal of Hypertension, 2022
Objective: To evaluate the incidence of cardiovascular (CV) and kidney outcomes and its predictors in treated resistant hypertensive (rHTN) patients. Design and method: We studied 117 rHTN patients and 114 controlled hypertensives (cHTN) patients on a triple fixed-dose combination of RAAS blockers / CCB / thiazide or thiazide-like diuretic. Patients with rHTN treated with the same type of triple fixed-dose combination in maximally tolerated doses plus the individually defined most effective fourth-line agent (spironolactone/eplerenone 56.1%, torasemide 26.8%, nebivolol 14.6%, moxonidine 2.5%); the fifth class of antihypertensive drug was added for 35.2 % of patients. A composite CV (CV death, myocardial infarction and/or revascularization, stroke, atrial fibrillation, and peripheral arterial disease) and kidney outcome (dialysis or GFR decline by 40% or greater) were estimated after five years (a mean follow-up 5.1 ± 0.1). The combined endpoint was defined as total CV and renal outcome events. Results: The goal office and 24-h BP were achieved at 49.6 and 34.2 % rHTN patients by the end of 5-year follow-up. During follow-up the incidence of all outcomes were higher at rHTN patients compared to cHTN pts: composite CV events (26.5 % vs 7 %, P = 0.001), kidney outcomes (4.3 % vs 0.9 %, P = 0.01), and diabetes (3.4 % vs 0.9 %, P = 0.02). The independent predictors of combined end point identified by multivariant logistic regression analysis were initial 24-h systolic BP ( = 0.099; OR = 1.10; 95 % CI 1.03 – 1.18; P = 0.008), blood concentration of endothelial progenitor cells (CD45+/CD34+) ( = - 0.89; OR = 0.41; 95 % CI: 0.21 – 0.79), P = 0.007) and citrulline ( = - 0.89; OR = 1.13; 95 % CI: 1.07 – 1.20; P < 0.001). Conclusions: Despite significant improvement in BP control the incidence of CV and renal outcomes in rHTN patients were higher than in cHTN patients. The independent predictors of combined CV and renal events were higher baseline systolic blood pressure, citrulline plasma level, and low concentration of endothelial progenitor cells.
Effect of multicomponent therapy on left ventricular diastolic function in resistant hypertension patients
O. O. Matova, L. А. Mishchenko, O. B. Kuchmenko
Ukrainian Journal of Cardiology, 2021
The aim – to determine prognostic factors of improving left ventricular diastolic function (LV DF) in resistant hypertension (RH) patients (pts) treated with multicomponent antihypertensive therapy during three years.Materials and methods. 102 patients with true RH were included. Patients received triple fixed combination (blocker of the renin-angiotensin-aldosterone system / calcium antagonist / diuretic), to which has been added a fourth drug (spironolactone, eplerenone, moxonidine, torasemide or nebivolol). The state of LV DF was studied at the beginning and at the end of the study. Office and 24-h ambulatory blood pressure (BP) measurements, echocardiography, clinical characteristics, neurohumoral and proinflammatory status were assessed.Results and discussion. Impairment LV DF was detected in 75.5 % of pts. The first degree of LV diastolic dysfunction (DD) was observed in 63.7 %. The patients were divided into 2 groups: the first group included persons without initial impairment of LV DF (n=25), the second – pts with LV DD (n=77). Patients with LV DD were older, had a longer duration of hypertension, higher body mass index, 24-h urinary albumin excretion, office BP and 24-h ambulatory BP, more often (in 2 times) disorders of circadian BP rhythm and concomitant diabetes mellitus (DM). Left ventricular DD in 100 % of cases was associated with severe LV hypertrophy (LVH), increased plasma concentration of inflammatory proteins (CRP, fibrinogen), cytokines (IL-6, TNF-α), increased activity of leukocyte elastase, macrophage matrix metalloproteinase-12. The concentration in the blood of aldosterone, active renin, 24-h urinary excretion of metanephrines did not differ between the groups.Conclusions. Improvement and stabilization of LV DF occurred in parallel with regression of LVH (normalization of LVMI in 35.1 % of pts and significant decrease of LVMI in 64.9 %) against the background of decrease of BP and in the proportion of pts with disturbed circadian BP rhythm. The independent factors of the E/E’ ratio were the initial plasma concentrations of aldosterone (β=0.556; р=0.0001), glucose (β=0.366; р=0.0001), active renin (β=–0.223; р=0.004), 24-h urinary albumin excretion (β=0.188; р=0.016), age (β=0,192; р=0,023). The odds of an improvement in LV DF increased by 3.7 times, if the patient with RH had no DM, LVH regression occurred.
The use of single-pill combinations as first-line treatment for hypertension: Translating guidelines into clinical practice
Erika Campana, Vitória Cunha, Sigita Glaveckaite, Ivan Gruev, Guillaume Lamirault, Elke Lehmann, Stefano Masi, Liliane Mfeukeu Kuate, Larysa Mishshenko, Deborah I.D. Ona, Min Zaw Oo, Oana G.F. Tautu, Anna Vachulova, Ana-Maria Vintila, Jacek Wolf, Nadezhda Zvartau, Krzysztof Narkiewicz, Stephane Laurent
Journal of Hypertension, 2020
The 2008 European Society of Cardiology/European Society of Hypertension guidelines recommend the first-line prescription of two antihypertensive drugs in single-pill combinations (SPCs), also known as fixed-dose combinations, for the treatment of most patients with hypertension. This recommendation is based on a large amount of data, which shows that first-line treatment with SPCs supports reaching blood pressure targets rapidly and reducing cardiovascular outcome risk while keeping the therapeutic strategies as simple as possible and fostering adherence and persistence. As this approach constitutes a big shift from the stepped-care approaches that have been dominant for many years, practicing physicians have expressed concerns about using SPCs as first-line agents. In this review, we will discuss the barriers to the uptake of this recommendation. We will also offer suggestions to reduce the impact of these barriers and address specific concerns that have been raised.
Effectiveness of the triple single-pill combination of antihypertensive drugs in patients with presumable resistant hypertension
Л.А. Мищенко, Е.А. Матова, Е.И. Сербенюк
Kardiologija V Belarusi, 2020
Efficiency of monotherapy for blood pressure control: results of Ukrainian MAHNAT study
Ukrainian Journal of Cardiology, 2019
Resistant arterial hypertension: clinical and pathogenetic peculiarities and predictors of therapy effectiveness
L. A. Mishchenko, O. G. Kupchynska, O. O. Matova, K. I. Serbeniuk, O. V. Gulkevych
Ukrainian Journal of Cardiology, 2019
Resistant arterial hypertension in patient with pheochromocytoma/paraganglioma
L. A. Mishchenko, L. V. Bezrodna, O. O. Matova, O. A. Tovkay, P. O. Lishchynskyi, A. V. Ratushnyak, K. I. Serbeniuk, V. B. Bezrodnyi, O. V. Gulkevych
Ukrainian Journal of Cardiology, 2019
Rivaroxaban with or without aspirin in stable cardiovascular disease
John W. Eikelboom, Stuart J. Connolly, Jackie Bosch, Gilles R. Dagenais, Robert G. Hart, Olga Shestakovska, Rafael Diaz, Marco Alings, Eva M. Lonn, Sonia S. Anand, Petr Widimsky, Masatsugu Hori, Alvaro Avezum, Leopoldo S. Piegas, Kelley R.H. Branch, Jeffrey Probstfield, Deepak L. Bhatt, Jun Zhu, Yan Liang, Aldo P. Maggioni, Patricio Lopez-Jaramillo, Martin O’Donnell, Ajay K. Kakkar, Keith A.A. Fox, Alexander N. Parkhomenko, Georg Ertl, Stefan Störk, Matyas Keltai, Lars Ryden, Nana Pogosova, Antonio L. Dans, Fernando Lanas, Patrick J. Commerford, Christian Torp-Pedersen, Tomek J. Guzik, Peter B. Verhamme, Dragos Vinereanu, Jae-Hyung Kim, Andrew M. Tonkin, Basil S. Lewis, Camilo Felix, Khalid Yusoff, P. Gabriel Steg, Kaj P. Metsarinne, Nancy Cook Bruns, Frank Misselwitz, Edmond Chen, Darryl Leong, Salim Yusuf
New England Journal of Medicine, 2017
Effect of irbesartan, an antagonist of AT-1 receptors for angiotensin II, on L-arginine metabolism in arterial hypertension
Fiziolohichnyi Zhurnal Kiev Ukraine 1994, 2002

Larysa Mishchenko

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications